Study of the Implementation of Telehealth-Supported LARC Provision in School-Based Health Centers

Sponsor
Columbia University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04840836
Collaborator
(none)
113
1
24.3
4.6

Study Details

Study Description

Brief Summary

This is a prospective observational cohort study that will include SBHC patients at the 6 participating SBHCs who receive a telehealth reproductive health visit as part of their care. Information will be collected during patient interviews in the follow-up observation period regarding LARC initiation, satisfaction and continuation.

Aim 1. Quantify uptake of LARC (contraceptive implant, IUD) within the SBHC network following implementation of telehealth-supported LARC provision.

Aim 2: Describe the implementation of telehealth-supported long-acting reversible contraception (LARC) service provision in school-based health centers (SBHCs) using mixed methods.

Aim 3: Quantify LARC continuation, as in absolute continuation rate 12 months post-initiation, with analyses also examining continuation at 6 months follow-up period, among LARC initiators within the SBHC network following implementation of telehealth-supported LARC provision.

Aim 4: Compare continuation rates across dimensions of telehealth experience.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Telehealth-supported LARC provision

Detailed Description

Long acting reversible contraceptives (LARCs) are safe and effective for adolescents, but low rates of use among this population and early discontinuation due to method dissatisfaction limits their potential to reduce unintended pregnancy. Reducing barriers for obtaining LARCs by adolescents who want to use them is key in reducing risk of unintended pregnancy. Data will be collected from patients who are receiving same-day LARC as a part of their normal care via telehealth services in school-based health centers (SBHCs). This implementation model, therefore, has the potential for replication and scale-up with wide reach. The findings from this study, given the SBHC setting, have the potential to inform and improve LARC service delivery for adolescents far beyond New York City and the SBHC setting.

Study Design

Study Type:
Observational
Anticipated Enrollment :
113 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Prospective Observational Study of the Implementation of Telehealth-Supported LARC Provision in School-Based Health Centers
Actual Study Start Date :
Apr 20, 2021
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Telehealth-supported LARC provision

Patients who receive care at the SBHC provide informed consent for care, as well as record review for quality assurance purposes. Analyses will include female patients who have a "reproductive health visit," which includes contraceptive counseling, contraceptive management, or contraceptive method initiation, during the study period. Patients who have a telehealth consultation with a SBHC medical provider for LARC services (conservatively estimated n=113) will be considered enrolled patients once the data are extracted from the EHR.

Behavioral: Telehealth-supported LARC provision
Provision of LARC in routine care will include a hybrid model of telehealth-supported long-acting reversible contraception (LARC) service provision in a network of 6 school-based health centers (SBHCs) in New York City that serve adolescents and young adult high school students age 13-22 years (hereafter referred to as "adolescents").
Other Names:
  • LARC method
  • Outcome Measures

    Primary Outcome Measures

    1. Uptake of LARC (contraceptive implant, IUD) within the SBHC network following implementation of telehealth-supported LARC provision [Up to 2 years]

      Among all patients who had a telehealth visit for contraceptive counseling, quantify the number/rate of telehealth LARC consultations and LARC initiations overall, and compare by LARC type (contraceptive implant vs. IUD) using data collected from patient interviews.

    2. Proportion of patients reported being satisfied with telehealth-supported care [Up to 2 years]

      A qualitative interview and a quantitative survey will be used to assess LARC patients' experience and satisfaction with telehealth-supported care. Patients will be assessed by investigator as satisfied or not satisfied based on their responses.

    3. Change in LARC continuation rate over a follow-up period among LARC initiators within the SBHC network following implementation of telehealth-supported LARC provision [At 6 months and 12 months post LARC initiation]

      Using EHR data for all patients who initiated LARC, investigator will use Kaplan-Meier survival curves to assess LARC discontinuation overall, and Cox proportional hazard models to compare LARC continuation by LARC type. Continuation rates will be expressed both as rates at 6 months and 12 months post-initiation, and using Kaplan-Meier curves to model discontinuation.

    4. Continuation rate across dimensions of telehealth experience [Up to 2 years]

      Merging electronic health record (EHR) data on method continuation with baseline survey data on the telehealth experience, we will compare, using Cox proportional hazard models, continuation (overall and within LARC type): by telehealth experience (e.g. satisfaction with telehealth).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    13 Years to 22 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • an enrolled patient at the participating SBHC

    • age 13-22 years

    • female

    • had a visit at the SBHC during the study period that is coded as a "reproductive health visit" including contraceptive counseling, contraceptive management, and contraceptive method initiation

    Exclusion Criteria (specifically for Aims 2 and 3):
    • are younger than age 13 years

    • are older than age 22

    • are not an enrolled patient of the participating SBHCs

    • did not initiate a LARC method

    • are a person without a uterus

    • are unable to read, speak, and understand either English or Spanish

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Columbia University Irving Medical Center New York New York United States 10032

    Sponsors and Collaborators

    • Columbia University

    Investigators

    • Principal Investigator: Samantha Garbers, PhD, Associate Professor of Population & Family Health

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Columbia University
    ClinicalTrials.gov Identifier:
    NCT04840836
    Other Study ID Numbers:
    • AAAT6596
    First Posted:
    Apr 12, 2021
    Last Update Posted:
    Jul 19, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Columbia University

    Study Results

    No Results Posted as of Jul 19, 2022